ライフサイエンスコーパス: gene delivery system

1 ar polyethylenimine (PEI)-containing in vivo gene delivery system.

2 as it identifies osteoclasts as an ideal CD gene delivery system.

3 erived from lentiviruses provide a promising gene delivery system.

4 ted this effect using an adenovirus-mediated gene delivery system.

5 Plasmids may have unique advantages as a gene delivery system.

6 position, size and multifunctionality of the gene-delivery system.

7 discuss the recent discoveries on non-viral gene delivery systems.

8 ed with DNA plasmids to create peptide-based gene delivery systems.

9 ons, ranging from nanostructures to nonviral gene delivery systems.

10 e availability of in vivo cell-type-specific gene delivery systems.

11 a new transfection multiplier for non-viral gene delivery systems.

12 rus being developed as a vector for clinical gene delivery systems.

13 capsids accommodating larger DNA cargoes as gene delivery systems.

14 systemically delivered nanoparticle nonviral gene delivery systems.

15 use lungs, superior to several gold standard gene delivery systems.

16 ween toxicity and transfection efficiency in gene delivery systems.

17 ns in nanoelectronics, sensing, and drug and gene delivery systems.

18 s on the development of efficient, non-toxic gene delivery systems.

19 examine the effectiveness of novel non-viral gene delivery systems.

20 ic, efficient, tumor cell- specific systemic gene delivery systems.

21 fficiency of G100R Env would be an asset for gene delivery systems.

22 ach should be useful for the design of other gene delivery systems.

23 ducers and analyzed entirely using transient gene delivery systems.

24 e livers using the in situ DNA injection and gene delivery systems.

25 lethanolamine are highly effective non-viral gene delivery systems.

26 the rational design of optimal peptide-based gene delivery systems.

27 a promising new class of synthetic nonviral gene delivery systems.

28 ies in the development of safe and efficient gene-delivery systems.

29 n that of commonly used cationic lipid-based gene-delivery systems.

30 ene expression in polycation-based, nonviral gene delivery systems, a number of CQ analogues with var

31 seases, is currently hampered by the lack of gene delivery systems able to cross the blood-brain barr

32 In contrast to other gene delivery systems, adeno-associated virus vectors sh

33 biodistribution and metabolism of non-viral gene delivery systems administered systemically are dire

34 to be successful, the development of proper gene delivery systems and hypoxia-regulated gene express

35 ans-splicing system is adaptable to multiple gene delivery systems, and it presents new opportunities

36 Thus, gene therapy using a retrovirus-based gene delivery system appears to be a feasible approach t

37 y for health care will not be realized until gene delivery systems are capable of achieving efficient

38 Non-viral gene delivery systems are one of the most potential alte

39 We previously reported a gene delivery system based on a fiber gene-deleted Ad ty

40 The availability of a stable gene delivery system based on a multiply attenuated lent

41 We formulated a new gene delivery system based on targeted liposomes.

42 herapy, and allow for the development of new gene delivery systems based on in vitro-generated papill

43 Here we present a non-viral gene-delivery system based on multisegment bimetallic na

44 AVs) have attracted considerable interest as gene delivery systems because they show long-term expres

45 lular and intracellular limitations of other gene delivery systems by binding reversibly and condensi

46 demonstrates that the Agrobacterium-mediated gene delivery system can be used to study the cis- and t

47 ansposon system is a highly active non-viral gene delivery system capable of integrating defined DNA

48 The single-plasmid gene delivery system carries both the piggyBac transposa

49 rexpression of caveolin-1, via an adenoviral gene delivery system, clearly accelerated endothelial ce

50 requires systemic delivery systems, a novel gene delivery system composed of liposome/protamine/DNA

51 The focus of this review is on gene delivery systems consisting merely of peptides with

52 Here we report a gene-delivery system consisting of a Sleeping Beauty (SB

53 The combined hRK and AAV gene delivery system could be an effective gene therapy

54 We then delve into detail about drug and gene delivery systems currently in preclinical and clini

55 the subject of intense research as non-viral gene delivery systems, due to their flexible properties,

56 racterization of different nanosized drug or gene delivery systems, e.g., polymers, nanoparticles, mi

57 ested in developing a noninvasive cell-based gene delivery system for the CNS that exploits the natur

58 The goal of this study was to develop a gene delivery system for the prolonged and controlled re

59 advances in the development of peptide-based gene delivery systems for delivery of different types of

60 Adaptation of in vitro optimized polymeric gene delivery systems for in vivo use remains a signific

61 n made to exploit cardioprotective drugs and gene delivery systems for myocardial infarction (MI).

62 Retroviral gene delivery systems for RNA polymerase II (RNA pol II)

63 The development of gene delivery systems for therapeutic use involves vecto

64 ine and suggest the potency of a local IL-22 gene-delivery system for treating UC.

65 utility of the adeno-associated virus (AAV) gene delivery system has been validated by the regulator

66 The adeno-associated virus (AAV) vector gene delivery system has shown promise in several clinic

67 s have been prepared, and their potential as gene delivery systems has been evaluated in comparison w

68 Both viral and nonviral vector gene delivery systems have been used to target specific

69 mbinant adeno-associated virus (rAAV) vector gene delivery systems have demonstrated great promise in

70 Non-viral gene delivery systems have the potential to create viabl

71 Therapeutic delivery of drug and gene delivery systems have to traverse multiple biologic

72 r gene, using an in vivo adenoviral mediated gene delivery system in a murine model.

73 pression, making them the most popular viral gene delivery system in clinical trials, with three AAV-

74 irus (MLV) is currently the most widely used gene delivery system in gene therapy trials.

75 apeutic effectiveness of this erythropoietin gene delivery system in vitro.

76 -mediated and cationic liposome-mediated E1A gene delivery systems in an orthotopic breast cancer ani

77 posomal, PEI, dendrimer, stem cell and viral gene delivery systems in order to determine the techniqu

78 t prevalent in current nonviral polycationic gene-delivery systems in which the polycationic nature o

79 Variations in gene delivery systems, including virus-type and latency

80 transduction by using an HIV-1-based vector gene delivery system into various human cell types inclu

81 hly regulated manner; the design of nonviral gene delivery systems is an illustrative example.

82 To determine its utility as a gene delivery system, it was important to assess the epi

83 ith the RIPtk gene, delivered by a liposomal gene delivery system, maintained their blood glucose lev

84 Cytotoxic gene-delivery systems may compromise these processes and

85 Of the many reported gene delivery systems, metal complexes with high affinit

86 Synthetic nanoparticle-based gene delivery systems offer highly tunable platforms for

87 execution of inhaled gene therapy, including gene delivery systems, primary physiological barriers an

88 This synergistic gene delivery system provides a viable method for highly

89 Self-assembled synthetic gene delivery systems represent the bottom-up approach t

90 ormone gene formulated in an optimal peptide gene delivery system show an increase in gene expression

91 for breast cancer, consisting of a nonviral gene delivery system (SN) and a proapoptotic gene, bik.

92 ent of fusion resulted in a highly efficient gene delivery system specific for liver cells in culture

93 Compared with viral vectors, synthetic gene-delivery systems, such as liposomes and polymers, o

94 The demonstration of an efficient gene delivery system targeted specifically to SMCs provi

95 The design of a non-viral gene delivery system that can release a functional nucle

96 aggregation behavior of a potential drug and gene delivery system that combines branched polyethylene

97 a novel simian virus (SV) 40-derived vector gene delivery system that efficiently transduces human l

98 We have constructed a recombinant adenovirus gene delivery system that is capable of undergoing growt

99 r a preclinical proof-of-concept for a novel gene delivery system that offers an effective intratrach

100 We have developed a gene delivery system that utilizes a cell-binding helper

101 roach offers a new perspective on developing gene delivery systems that specifically target astrocyte

102 ry and balance function is likely to require gene delivery systems that target auditory and vestibula

103 cs highlight the critical need for precision gene delivery systems that target specific organs and ce

104 ovirions (HPV-PsVs) approach is an effective gene-delivery system that can prime or boost an immune r

105 eve to be a novel microinjection-based local gene-delivery system that is capable of targeting the in

106 a plasmid DNA using polyethylenimine as the gene delivery system, thereby circumventing the problem

107 To further understand the AAV gene delivery system, this study investigates the role o

108 In contrast to other viral gene delivery systems, this minimally invasive procedure

109 ciently, we employed an inducible adenoviral gene delivery system to achieve tightly controlled expre

110 lineage cells could function as a cell-based gene delivery system to bone cancers.

111 oward that end, we constructed an adenovirus gene delivery system to enable robust, glial-specific, a

112 yocytopoiesis, we used a lentiviral-mediated gene delivery system to prevent physiologic down-regulat

113 We expect this NP-mediated gene delivery system to provide safe and sustained relea

114 ropylenimine dendrimer is a highly promising gene delivery system to the brain.

115 show that adv is a highly efficient in vivo gene delivery system to treat experimental human melanom

116 We have now used two gene delivery systems to target TGF alpha overexpression

117 These data confirm that this EPO gene delivery system using a bioreducible polymeric carr

118 We developed an efficient T-DNA-based gene delivery system using Agrobacterium tumefaciens to

119 Although the development of gene delivery systems via non-viral-mediated methods is

120 A polymeric gene delivery system was developed to deliver the solubl

121 A polymeric gene delivery system was developed to deliver the solubl

122 transduction efficacy of a lentivirus based gene delivery system was not augmented.

123 The gene delivery system was tested in healthy rodents and p

124 An in vivo adenoviral gene delivery system was utilized to assess the effect o

125 adenovirus-mediated gene transfer as a model gene delivery system, we cloned the peptide SIGYPLP and

126 terize the use of baculovirus as a mammalian gene delivery system, we examined the status of transduc

127 To address the need for more efficient gene delivery systems, we have developed replication-com

128 e problem of creating nontoxic but effective gene-delivery systems, we hypothesized that by optimizin

129 The peptide-based gene delivery systems were tested for transfection effic

130 stimuli triggered, photothermal controllable gene delivery system, which can be further applied to ma

131 ids of transposon DNA or minicircle DNA, the gene-delivery system, which we named MAJESTIC (for 'mRNA

132 may also aid in the development of nonviral gene delivery systems with increased efficiency.

133 In contrast, gene delivery systems with RNA pol III-based expression

134 rane-particle interactions in the context of gene delivery systems, with the aim to guide the design